GRAS Act
- Sponsor
- Rep. Pallone, Frank [D-NJ-6]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Aug 12, 2025
Bottom line
The GRAS Act aims to enhance FDA oversight of food ingredients by requiring pre-market notification for GRAS substances and periodic safety reassessments, shifting from a self-determination model to a more active regulatory role for the FDA.
What it actually does
This bill, the "GRAS Act," amends the Federal Food, Drug, and Cosmetic Act to significantly alter the regulatory framework for substances "generally recognized as safe" (GRAS). It removes the GRAS exemption from the definition of a food additive, requiring manufacturers to notify the FDA before using new GRAS substances and obtain a "statement not to object." The bill also mandates regular FDA reassessments of existing GRAS substances and other food additives, and establishes new fees to fund these activities.
Proponents argue
Proponents argue that the current GRAS system, which largely relies on industry self-determination without mandatory FDA review, poses a public health risk by allowing potentially unsafe chemicals into the food supply. They contend that this bill will close a critical loophole, ensure greater transparency, and provide the FDA with the necessary authority and resources to proactively evaluate the safety of food ingredients, including those already on the market, thereby protecting consumers from harmful substances.
Opponents contend
Opponents might argue that the bill imposes an unnecessary regulatory burden on the food industry, potentially stifling innovation and increasing costs for consumers. They may contend that the existing GRAS system, when properly applied, is sufficient and that mandatory pre-market notification and reassessments could lead to significant delays in bringing new ingredients to market, or removing existing ones without clear scientific justification, ultimately harming businesses and limiting consumer choice.
The bill is relatively short and clearly structured, making it accessible for a reader to understand its core provisions within a reasonable timeframe.
Section 2(a), amending Section 201(s) of the FFDCA.
Reclassifying GRAS Substances as Food Additives
This section fundamentally changes how "generally recognized as safe" (GRAS) substances are treated under federal law. Previously, GRAS substances were exempt from the definition of a "food additive." This amendment removes that exemption, meaning that GRAS substances will now be considered a type of food additive, subjecting them to the regulatory framework of food additives. It also formally defines "generally recognized as safe" within the FFDCA.
Supporters argue
Supporters argue this closes a significant loophole that allowed many substances to enter the food supply without direct FDA review, enhancing consumer safety by bringing these substances under a more robust regulatory framework.
Critics contend
Critics might argue this creates an unnecessary regulatory burden, as the GRAS determination process, when followed correctly, already ensures safety through expert consensus.
Tradeoffs
The tension lies between industry flexibility and self-regulation versus increased government oversight and consumer protection.
Section 3, adding subsection (l) to Section 409 of the FFDCA.
Pre-Market Notification and FDA Non-Objection for GRAS Substances
This provision requires any person intending to treat a new food substance or a substance not marketed before the enactment date as GRAS to submit a notice to the FDA. This notice must include comprehensive scientific data demonstrating safety, including information on cumulative effects, carcinogenicity, and reproductive/developmental toxicity. The substance can only be used if the FDA issues a written statement of "not to object" to the GRAS determination, based on the adequacy of the submitted data and absence of conflicts of interest. The FDA has 180 days (with a possible 90-day extension) to make this determination.
Section 4, adding subsection (m) to Section 409 of the FFDCA.
Periodic Safety Reassessment of Existing Food Substances
This section mandates that the FDA systematically reassess the safety of at least 10 food additives, GRAS substances, color additives, prior-sanctioned substances, or food contact substances (or classes thereof) every three years. The FDA can require manufacturers to submit updated safety evaluations, including new data on dietary exposure, cumulative effects, and toxicity. If safety concerns arise, the FDA can revoke its "not to object" statement for GRAS substances.
Section 5, adding subsection (n) to Section 409 of the FFDCA.
Standardized Definitions for Carcinogenic, Toxicity, and Conflict of Interest
This section introduces several key definitions to the FFDCA, including "carcinogenic," "class" (of substances), "conflict of interest," "cumulative effects," "developmental toxicity," "food contact substance," "new use," and "reproductive toxicity." These definitions provide clear standards for the scientific evaluations and determinations required under the new GRAS notification and reassessment processes.
Section 6, amending Section 743 of the FFDCA.
Establishment of User Fees for GRAS Notifications and Reassessments
This section amends the FFDCA to establish new user fees. It requires persons filing petitions or submitting notices for food additives (including GRAS substances under the new framework) to pay fees. It also requires persons manufacturing or receiving food substances subject to reassessment under the new Section 409(m) to pay fees. These fees are intended to cover 100% of the FDA's costs for reviewing notices, issuing regulations, and conducting reassessments, starting in fiscal year 2026.
The Secretary shall object to a GRAS determination if an expert providing supporting data "appears to have a conflict of interest, as determined pursuant to guidance issued by the Secretary."
Section 3, amending Section 409(l)(5)(B) of the FFDCA.
Why it matters:Standard legislative practice to delegate detailed policy implementation to agency guidance, allowing flexibility. However, the specifics of what constitutes a conflict of interest are highly consequential.
Case for: Supporters argue that allowing the Secretary to issue guidance provides necessary flexibility to adapt to evolving ethical standards and scientific practices, ensuring the conflict of interest policy remains effective.
Case against: Critics might argue that leaving the definition of "conflict of interest" to future guidance creates uncertainty for industry and could lead to arbitrary or overly broad interpretations without explicit legislative parameters.
Estimated impact: High, as the definition of conflict of interest will determine the eligibility and credibility of expert opinions in GRAS determinations, potentially excluding certain industry-affiliated scientists.
Both new GRAS notifications and periodic reassessments must include information on "cumulative effects" of the substance and demonstrate that the substance has not been found to induce reproductive or developmental toxicity, "including through an endocrine mode of action."
Section 3, amending Section 409(l)(2)(B) and (F); Section 4, amending Section 409(m)(2)(B) and (F).
Why it matters:Technical legislative drafting, specifying the scope of scientific inquiry without highlighting it as a separate policy point. This is standard for detailed regulatory bills.
Case for: Proponents argue that explicitly requiring consideration of cumulative effects and endocrine disruption addresses critical gaps in past safety assessments, reflecting modern toxicology and protecting against subtle but widespread harms.
Case against: Industry might argue that assessing cumulative effects, especially for chemically or pharmacologically related substances, is scientifically challenging and resource-intensive, potentially leading to delays or overly conservative determinations.
Estimated impact: High, as these requirements significantly broaden the scope and complexity of safety studies, potentially leading to more substances being flagged for concern.